Market Cap (In USD)
36.25 Million
Revenue (In USD)
-
Net Income (In USD)
-16.82 Thousand
Avg. Volume
192.33 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.808-1.96
- PE
- -
- EPS
- -
- Beta Value
- -3.356
- ISIN
- US6793451088
- CUSIP
- 679345108
- CIK
- 1849296
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Gary S. Jacob Ph.D.
- Employee Count
- -
- Website
- https://www.okyopharma.com
- Ipo Date
- 2022-05-17
- Details
- OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
More Stocks
-
FAS
-
OCX
-
0JTQLear Corporation
0JTQ
-
0Y5XPentair plc
0Y5X
-
NUCLEUSNucleus Software Exports Limited
NUCLEUS
-
NGIL
-
PANAMAPETPanama Petrochem Limited
PANAMAPET
-
3485